Bio-Rad Aims to Launch GnuBio Sequencer within Two Years, Discloses Purchase Price of up to $110M | GenomeWeb

This article was originally published May 12.

NEW YORK (GenomeWeb) − Bio-Rad Laboratories plans to commercialize GnuBio's droplet-based sequencing technology within two years, the company said last week. It also disclosed that it paid $40 million in cash for GnuBio when it acquired the firm last month, and could make up to $70 million in development and sales milestone payments over the next three years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.